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1. Introduction 
He could fit in the palms of both hands, seemed to look at you beseechingly while you rushed to thread 
a vein and snake a tube down a tiny nostril of this 24 week preemie. Already exposed to the prenatal 
stress that culminated in premature delivery, he has been further exposed to the stress associated with 
the separation from his mother and multiple medical interventions. Like other premature babies, he is 
more vulnerable to invasive infections from bacteria and viruses; moreover, the delayed development 
of his gut-blood-brain barriers could expose him to potential neurotoxins.  
Such infants are up to 4 times more likely to develop autism. If their mothers had allergies, 
mastocytosis or an autoimmune disease, this risk almost doubles. 
Autism Spectrum Disorders (ASD) are pervasive developmental disorders that include Autistic 
Disorder and Asperger’s Disorder, although Pervasive Developmental Disorder-Not Otherwise 
Specified (PDD-NOS) is frequently included (Johnson & Myers, 2007). ASD are characterized by 
variable deficits in social skills, stereotypic behaviors, and a wide range of behavioral and 
learning problems. ASD manifest during early childhood and at least 30% present with sudden 
clinical regression of development around 3 years of age (Matson J.L. & Kozlowski A.M., 2010; 
Zappella, 2010). Over the last 20 years, there has been an impressive rise in ASD with current 
prevalence estimates of 1/100 children (Fombonne, 2009; Kogan et al., 2009).  
In the majority of cases, the cause of ASD is unknown (Levy et al., 2009). Some autism 
susceptibility genes have been identified (Weiss et al., 2009), but gene interactions with 
environmental factors are increasingly suspected (Deth et al., 2008; Herbert, 2010). Recent 
reviews have focused mostly on genomic screens that suggest there are multiple gene 
interactions in autism; however no gene abnormality alone can explain the apparent 
increase in ASD prevalence (Durkin et al., 2010; Herbert, 2010; Miles, 2011). Increasing 
evidence suggests that there are different ASD endophenotypes, even within the ASD 
spectrum (Palmieri & Persico, 2010).  
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Intrauterine conditions in combination with external environmental triggers or specific 
genotypes, may lead to developmental disturbances. Indeed, an epidemiologic study, nested 
within a cohort of 698 autistic children in Denmark, concluded that prenatal environmental 
factors and parental psychopathology are associated with the risk of autism and these 
factors seem to act independently (Larsson et al., 2005). It is also recognized that tuberous 
sclerosis, a neurocutaneous disorder, involves autistic symptoms in approximately 40-45% 
of cases (Smalley, 1998). It has been proposed that this partial penetrance may be the result 
of an interaction between gene mutations and environmental factors, such as gestational 
immune activation (Ehninger et al., 2010). An early environmental insult, such as prenatal 
infection could cause long-term changes in neural function by altering epigenetic 
programming. Studies on rodents suggest that during early development, environmental 
signals can activate intracellular pathways, leading to epigenetic changes and consequently 
changes in neural function (Zhang & Meaney, 2010). In fact, variations in early maternal care 
affect stress responses in the offspring by altering the methylation status of the 
glucocorticoid receptor gene promoter (Weaver et al., 2004).   
2. The role of prematurity 
Premature births (delivery prior to 37 weeks gestation) currently account for 12.7% of all births 
in the United States, a rise of approximately 20% in the past two decades (MacDorman et al., 
2010).  Although infants less than 28 weeks gestation are at the highest risk for long-term 
neurologic problems, infants born between 32 and 36 weeks are increasingly recognized to be 
at risk for neurologic injury, such as leukomalacia and gray matter damage (Adams-Chapman, 
2006; Argyropoulou, 2010; Okumura et al., 2010; Volpe, 2009). Clinical, epidemiological and 
experimental studies have revealed that key factors, such as inflammation and oxidative stress 
contribute considerably to white- and grey-matter injury in premature infants, whose brains 
are particularly susceptible to damage (Kaindl et al., 2009). In infants surviving premature 
birth, cerebellar hemorrhagic injury is also associated with a high prevalence of 
neurodevelopmental disabilities (Limperopoulos et al., 2007). The resulting long-term 
neurologic complications may include learning difficulties, behavioral and socio-emotional 
concerns, and poor general health outcomes.  These vulnerable near-term (late preterm) 
infants make up the greatest number of premature births and account for the significant 
increase in the rate of prematurity in the recent years (Martin, 2011). Although the etiology of 
premature delivery is often unknown, chronic in utero inflammation or infection are well-
described conditions that lead to preterm labor and birth (Dubicke et al., 2010; Snegovskikh et 
al., 2009; Thaxton et al., 2010).  Inflammation itself has been strongly associated with adverse 
neurodevelopmental outcomes in premature infants (Lin et al., 2010; Rovira et al., 2011). An 
additional 5-8% of deliveries are complicated by pre-eclampsia or gestational diabetes, which 
may lead to placental insufficiency, abnormal growth, and postnatal metabolic imbalance.  
Excessive production of cortocotropin releasing hormone (CRH) has also been linked to 
preterm labour (Campbell et al., 1987; Warren et al., 1992). A number of cytokines are known 
to cause in vitro secretion of CRH from cultured placental trophoblasts, including IL-1 and IL-
6 (Petraglia et al., 1990). In turn, CRH stimulates release of IL-6 from peripheral blood 
mononuclear cells, which infiltrate the fetal membranes and the placenta in increasing 
numbers during intrauterine infection (Angioni et al., 1993).  
Recent reports suggest a potential association between preterm birth and autism. In 
particular, one retrospective study investigated preterm children born in Atlanta, GA (1981-
93) who survived to three years of age, and identified rates of autism through the 
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Metropolitan Atlanta Developmental Disabilities Surveillance Program.  Preterm birth prior 
to 33 weeks gestation was associated with a two-fold higher risk of autism in all infants 
(Limperopoulos et al., 2008).  Interestingly, this study reported a gender-specific, four-fold 
increased risk for autism accompanied by mental retardation in preterm girls with low birth 
weight (LBW) (<2500 g at birth). Another study performed a prospective follow-up 
assessment on 91 ex-preterm very low birth weight (VLBW) infants (<1500 g at birth) at the 
mean age of 22 months and found 26% of these children to have a positive Modified 
Checklist for Autism in Toddlers (M-CHAT) test (Kinney et al., 2008). A more recent study 
found that 21% of infants (212/988) born before 28 weeks of gestation screened positive 
using M-CHAT (Kuban et al., 2009) as compared to 5.7% of healthy children 16-30 months 
old (Kleinman et al., 2008). Much higher rates of positive testing on M-CHAT were found in 
premature children with motor or sensory impairment (Kuban et al., 2009). It should be 
noted, however, that a positive CHAT test must be confirmed with more specific diagnostic 
tools, such as the Autism Diagnostic Observation Schedule-Generic (ADOS-G, a patient 
observational tool) or the Autism Diagnostic Interview-Revised (ADI-R, a parent interview 
tool) which provide a more reliable diagnosis for ASD. A prospective study of all births less 
than 26 weeks gestation in 1995 in the United Kingdom and Ireland concluded that ex-
preterm children are at increased risk for ASD in middle childhood, compared with their 
term-born classmates, after psychiatric, clinical, IQ and SCQ (Social Communication 
Questionnaire) evaluations (Johnson et al., 2010).  
A cohort of 164 families with autistic children (Brimacombe et al., 2007) concluded that the 
increased risk of autistic disorders related to prematurity is primarily attributed to perinatal 
complications that occur more commonly among preterm infants, results also confirmed in a 
Swedish population-based case-control study (Buchmayer et al., 2009). A meta-analysis on 
prenatal risk factors for autism argued that evidence is insufficient to implicate individual 
prenatal factors in autism etiology, because many of the studies examined all available 
prenatal data using designs with methodological weaknesses, so that significant associations 
may have been observed by chance after multiple testing (Gardener et al., 2009). Findings from 
population-based studies suggest that suboptimal birth conditions are not independent risk 
factors for infantile autism, but rather clusters of them increase the risk of ASD (Maimburg & 
Vaeth, 2006). Finally, a more recent cohort study on infants born in Canada between 1990-2002 
concluded that perinatal risk factors including prenatal, obstetrical and neonatal 
complications, have a lesser overall effect on autistic outcomes among the genetically 
susceptible pediatric population, compared to children with low genetic susceptibility (Dodds 
et al., 2010). Reviews of studies evaluating neurobehavioral outcomes following preterm birth 
reveal a “preterm behavioral phenotype” characterized by symptoms of inattention, anxiety 
and social difficulties (Johnson & Marlow, 2011; Limperopoulos, 2009). 
3. Maternal autoimmune diseases 
The relationship between ASD and familial autoimmunity has long been recognized (Money 
et al., 1971), and has been supported by at least three large population-based studies 
discussed below; these studies utilized medical records and physician data to determine 
autoimmunity in families of ASD and typically-developing children.  
One case-control study nested within a cohort of infants born in California between 1995-1999, 
examined the association of “immune-related conditions” with ASD using health records and 
reported that prevalence of maternal psoriasis, asthma, hay fever and atopic dermatitis during 
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the second trimester of pregnancy correlated with over two-fold elevated risk of ASD in their 
children (Croen et al., 2005). The second cohort consisted of the pediatric population born in 
Denmark from 1993 through 2004 (n=689,196), in which 3,325 children were diagnosed with 
ASD including 1,089 cases of infantile autism. The study confirmed an association between 
family history of type 1 diabetes and infantile autism, as well as rheumatoid arthritis and ASD; 
it was also the first to show a significant association between maternal celiac disease and ASD 
(Atladottir et al., 2009). A significant association between parental rheumatic fever and ASD, as 
well as several significant correlations between maternal autoimmune diseases and ASD were 
investigated across 3 Swedish registries by means of a case-control study (n=1,227 ASD cases 
matched with 25 controls each) (Keil et al., 2010). Auto-antibodies against brain proteins have 
been reported in a number of mothers with children who developed autism (Croen et al., 
2008). A possible explanation for the link between maternal immune dysregulation and ASD 
would be the transfer of maternal autoantibodies to the developing fetus during pregnancy 
(Braunschweig et al., 2008; Croen et al., 2008; Singer et al., 2008; Zimmerman et al., 2007), 
resulting in abnormal neurodevelopment. This phenomenon was manifested in the offsprings 
of pregnant mice after their transfection with human systemic lupus erythematosus 
autoantibodies (Lee et al., 2009). A preliminary report also indicated that mothers with a 
diagnosis of mastocytosis during pregnancy had a high chance of having one or more children 
with autism (Theoharides, 2009). 
Results from animal modeling studies clearly indicate that maternal immune activation 
(MIA) can cause both acute and lasting changes in behavior and CNS structure and function 
in the offspring (Boksa, 2010). Administration of bacterial lipopolysaccharide (LPS), a cell 
wall component from Gram-negative bacteria, activates Toll-like receptor-4 (TLR-4) on 
immune cells leading to synthesis and release of TNF (Varadaradjalou et al., 2003), IL-1 and 
IL-6 (Supajatura et al., 2002). It was recently shown that IL-1 receptor antagonism prevented 
neurodevelopmental anomalies in pregnant rats after systemic end-of-gestation exposure to 
LPS (Girard et al., 2010). In addition to its direct detrimental effect on the placenta and fetal 
brain tissue, IL-1 induces selective release of IL-6 from mast cells (Kandere-Grzybowska et 
al., 2003). IL-6 appears critical for fetal brain development and social behavior development, 
as demonstrated in a poly(I:C) mouse model for MIA, where co-administration of anti-IL-6 
antibody prevented the social deficits and associated gene expression changes in the brain of 
the offspring (Smith et al., 2007). 
However, human studies investigating the role of prenatal infection in the pathogenesis of 
autism are limited, and mostly focused on viral infections (Chess, 1977; Libbey et al., 2005; 
Wilkerson et al., 2002). A recent nationwide study in Denmark including children born from 
1980 through 2005 points to an increased risk for ASD after maternal viral infection in the 
first trimester of pregnancy (adjusted hazard ratio = 2.98; CI: 1.29-7.15) or maternal bacterial 
infection in the second trimester of pregnancy (adjusted hazard ratio = 1.42; CI: 1.08-1.87) 
(Atladottir et al., 2010). Moreover, a number of rotaviruses have been isolated from 
asymptomatic neonates (Dunn et al., 1993). Viral double-stranded RNA like poly(I:C) 
induces release of TNF and IL-6 without degranulation from mast cells through viral TLR-3 
(Kulka et al., 2004).  
4. Autoimmunity in ASD children 
A recent study implied the presence of an endophenotype with complex immune dysfunction 
is present both in autistic children and their non-autistic siblings (Saresella et al., 2009). Brain-
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specific auto-antibodies are present in the plasma of many ASD individuals (Cabanlit et al., 
2007; Singh et al., 1997; Singh & Rivas, 2004). Such auto-antibodies suggest a loss of self-
tolerance to neural antigens during early neurodevelopment, but their precise role in autism 
remains unknown (Enstrom et al., 2009; Mostafa et al., 2008; Mostafa & Kitchener, 2009; Wills 
et al., 2007). They may indicate disruption of the blood-brain barrier (BBB), at least in a 
subgroup of patients. The presence of an auto-inflammatory response is also supported by the 
detection of certain inflammation markers. For instance, TNF was high in the cerebrospinal 
fluid (CSF) (Chez et al., 2007), and IL-6 gene expression was increased in the brain (Li et al., 
2009) of autistic patients. CSF and microglia of ASD patients had high levels of macrophage 
chemoattractant protein-1 (MCP-1) (Vargas et al., 2005), which is also a potent chemoattractant 
for mast cells (Conti et al., 1997). In contrast, ASD plasma levels of transforming growth factor-
beta1 (TGF-β1) were low (Ashwood et al., 2008), which is important in view of the fact that 
TGF-β1 inhibits mast cell function (Gebhardt et al., 2005). Many children with ASD also report 
gastrointestinal symptoms (Buie et al., 2010). In a few studies, examination of intestinal 
biopsies from children with regressive autism reveals features of an autoimmune mucosal 
pathology, that is not seen in other conditions or inflammatory bowel diseases (Ashwood et 
al., 2003; Torrente et al., 2002). 
Many of the epidemiologic, biochemical and pathologic findings could be explained 
through activation of mast cells, immune cells important in both innate and acquired 
immunity (Galli et al., 2005), as well as in inflammation (Theoharides & Kalogeromitros, 
2006). Mast cells are well-known for their leading role in allergic reactions, during which 
they are stimulated by IgE binding to high-affinity receptors (FcεRI), aggregation of which 
leads to degranulation and secretion of numerous pre-stored and newly-synthesized 
mediators, including IL-6 and TNF (Blank & Rivera, 2004; Kraft & Kinet, 2007; Schroeder et 
al., 1995; Schwartz, 1987; Serafin & Austen, 1987; Stone et al., 2010; Torigoe et al., 1997). In 
addition to IgE, many substances originating in the environment, the intestine or the brain 
can trigger mast cell activation (Theoharides et al., 2011). These include non-allergic 
environmental, infectious, neurohormonal and oxidative stress-related triggers, involving 
release of mediators selectively, without degranulation (Theoharides et al., 2007b). For 
instance, LPS activates TLR-4 on mast cells and induces selective release of TNF 
(Varadaradjalou et al., 2003), while IL-1 induces selective release of IL-6 (Kandere-
Grzybowska et al., 2003).  
Environmental toxins have been implicated in developmental neurotoxicity (Grandjean & 
Landrigan, 2006) and also in mast cell activation. In particular, polychlorinated biphenyl 
(PCB) (Hertz-Picciotto et al., 2008) and mercury (Young et al., 2008) have been associated 
with ASD, and both also activate mast cells (Asadi et al., 2010; Kempuraj et al., 2010; Kwon 
et al., 2002). Other mast cell triggers include bacterial and viral antigens, as well as peptides 
such as neurotensin (NT), which we reported to be increased in serum of young children 
with autism (Angelidou et al., 2010), and to induce mast cell release of extracellular 
mitochondrial DNA, which was also increased in the serum of these ASD patients (Zhang et 
al., 2010). This finding may be in addition to mitochondrial dysfunction reported in ASD 
(Giulivi et al., 2010; Palmieri & Persico, 2010). Given the fact that NT activates mast cells 
(Theoharides et al., 2004) and abundant NT is located in the gut (Castagliuolo et al., 1996), 
its elevated levels might lead to gut dysfunction in a cohort of autistic patients. NT also 
augments the action of CRH, which stimulates selective release of vascular endothelial 
growth factor (VEGF) (Cao et al., 2005). In fact, CRH acts synergistically with NT to increase 
vascular permeability (Donelan et al., 2006). 
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Mast cell-derived cytokines can also increase BBB permeability (Abbott, 2000; Theoharides 
& Konstantinidou, 2007). BBB disruption has been documented in brain inflammatory 
diseases, such as multiple sclerosis, where it precedes any pathological or clinical symptoms 
(Minagar & Alexander, 2003; Soon et al., 2007; Stone et al., 1995). We speculate that perinatal 
mast cell activation, in response to allergic or non-immune triggers, could disrupt the gut-
blood-brain barriers (Theoharides & Doyle, 2008) and permit neurotoxic molecules to enter 
the brain and result in brain inflammation, thus contributing to ASD pathogenesis (Fig. 1) 
(Theoharides et al., 2008). It is intriguing that mast cell-derived IL-9 induces intestinal 
permeability and predisposes to oral antigen hypersensitivity in children (Forbes et al., 
2008), while it also exacerbates newborn brain toxic lesions (Dommergues et al., 2000). 
Moreover, IL-33 can synergize with SP (Theoharides et al., 2010) and SCF (Drube et al., 2010) 
in stimulating mast cell TNF release, while it also activates glial cells to secrete pro-
inflammatory cytokines (Yasuoka et al., 2011). The possible involvement of mast cells 
(Theoharides et al., 2011) in ASD is also supported by the fact that many children with ASD 
report “allergic-like” symptoms (Angelidou et al., 2011).   
5. Perinatal stress 
Mast cells have been implicated in inflammatory conditions that worsen by stress 
(Theoharides & Cochrane, 2004) and in regulating BBB permeability (Esposito et al., 2002). It 
was shown that early life stress due to maternal separation resulted in an altered brain-gut 
axis; it was sufficient to cause an increase in the blood concentrations of pro-inflammatory 
cytokines after a challenge with LPS, and also an increase in plasma corticosterone 
(O'Mahony et al., 2009). The timing of prenatal stressors was investigated in a case-control 
study, recording mothers’ reports on exposure to stressors during each 4-week block of 
pregnancy. A higher incidence of stressors at 21-32 weeks gestation was found in autism, in 
consistency with the embryological age at which pathological cerebellar changes in autism 
are seen (Beversdorf et al., 2005). 
We propose that prenatal or perinatal stress may contribute to the development of ASD 
through excessive release of CRH. CRH is typically secreted from the hypothalamus, but it 
can also be secreted from the skin (Slominski et al., 2006) and nerve endings (Skofitsch et al., 
1985), where it exerts pro-inflammatory effects (Chrousos, 1995; Slominski et al., 2001; 
Theoharides et al., 2008). CRH can also be released from immune cells (Karalis et al., 1997) 
and mast cells (Kempuraj et al., 2004). In fact, CRH released from hair follicles can trigger 
mast cell proliferation (Ito et al., 2010). This form of tissue CRH sometimes called “immune 
CRH” may have an immunomodulatory role as an autocrine/paracrine mediator of 
inflammation during reproduction (Kalantaridou et al., 2007). One of the early effects of 
immune CRH is the activation of mast cells and the release of several pro-inflammatory 
cytokines (Theoharides et al., 2004). CRH was increased in the serum of mothers who 
delivered preterm babies and correlated with their level of anxiety during that period of 
pregnancy (Makrigiannakis et al., 2007).  Maternal serum CRH can cross the placenta, and 
potentially high amounts of CRH could be produced by the placenta itself in response to 
external or intrauterine stress (Grammatopoulos, 2008; Torricelli et al., 2011). CRH can then 
disrupt the BBB (Theoharides & Konstantinidou, 2007), which appears to be compromised 
in ASD patients, as indicated by the presence of autoantibodies against encephalogenic 
peptides (Cabanlit et al., 2007; Goines & Van de Water J., 2010; Singer et al., 2006; Vojdani et 
al., 2002; Wills et al., 2008). BBB disruption due to stress is dependent on both CRH 
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Fig. 1. Diagrammatic depiction of how perinatal immune activation may contribute to brain 
inflammation and autism. CRH, corticotropin-releasing hormone; IL, interleukin; LPS, 
lipopolysaccharide; MCP-1, macrophage chemoattractant protein-1; mtDNA, mitochondrial 
DNA; NT, neurotensin; PCB, polychlorinated biphenyl; poly(IC),polyinosinic:polycytidylic 
acid; ROS, reactive oxygen species; SP, substance P; TGFβ1, transforming growth factor-
beta1; TNF, tumor necrosis factor 
(Esposito et al., 2002) and mast cells (Esposito et al., 2001) and is associated with high serum 
IL-6 that is also mast cell-dependent (Theoharides & Konstantinidou, 2007). 
The effect of CRH may be relevant to the behavioral manifestations of ASD. ASD patients had 
high anxiety levels and were unable to handle stress appropriately (Gillott & Standen, 2007). 
Evening cortisol levels positively correlated to daily stressors in children with autism (Corbett 
et al., 2009). Moreover, increase in age of autistic children correlated with increased cortisol 
levels during social interaction stress (Corbett et al., 2010). CRH has also been shown to 
increase intestinal permeability of human colonic biopsies, while maternal separation stress 
and CRH are associated with a dysfunctional mucosal barrier in rodents (Soderholm et al., 
2002). A short period of restraint (Chandler et al., 2002) or maternal deprivation stress (Teunis 
et al., 2002) also increased the severity of experimental autoimmune encephalomyelitis.  
The presence of  maternal stress may explain why children born within a year of the first 
child that developed autism had a much higher chance of developing autism than if they 
were born two years later (Cheslack-Postava et al., 2011). Increased circulating CRH, directly 
or through immune cell release of other inflammatory and vasoactive molecules, can disrupt 
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the gut-blood-brain barriers during gestation and/or infancy and permit absorption of 
intestinal-derived inflammatory and neurosensitizing mediators. 
6. Other perinatal risk factors  
High weight gain in pregnancy has been considered an independent risk factor for autism in 
the offspring (Stein et al., 2006). Even though a clear mechanism is lacking, leptin is 
suspected to play a major role. Obese subjects have higher leptin levels than normal weight 
subjects (Considine et al., 1996; Dardeno et al., 2010). Additionally, it has been suggested 
that elevated plasma leptin levels during pregnancy are indicative of placental dysfunction 
(Hauguel-de et al., 2006). Placental insufficiency, possibly associated with anoxia, may also 
contribute to autism in the offspring (Glasson et al., 2004).  
Elevated plasma leptin levels were reported in children with regressive autism (n=37), 
compared with typically-developing controls (n=50) (Ashwood et al., 2007). One group also 
measured the variation of circulating leptin at baseline and after one year of follow-up in 35 
patients with “classic autism” (according to DSM-IV criteria) aged 14.1±5.4 years old. The 
authors reported significantly higher leptin values in the patients versus the controls 
(24.1±17.8 ng/ml vs 9.8±3.2 ng/ml at baseline; 33.5±21.4 ng/ml vs 11.1±3.9 ng/ml at one 
year), and leptin concentrations were not associated with obesity or pubertal status (Blardi 
et al., 2010). It is still unclear, however, if the alteration of leptin levels in autism is a primary 
event or a finding attributable to the disease. Plasma levels of leptin have also been 
investigated in patients with Rett syndrome (n=16), where it was found that leptin was 
significantly increased compared to healthy controls (n=16), but also did not correlate with 
obesity (Blardi et al., 2008), suggesting that there may be more to the actions of leptin in 
neurodevelopment than weight balance.  
The immunomodulatory properties of leptin were first reported on a mouse model, in 
which obese mice were found to have impaired cell-mediated and humoral immunity, 
attributed to possible lack of leptin (Chandra, 1980). The epigenetic status in adulthood was 
shown to be directionally dependent on prenatal nutritional status (Gluckman et al., 2007) 
and neonatal leptin administration late in the phase of developmental plasticity was able to 
reverse the developmental programming in rats (Vickers et al., 2005). Mast cells also express 
leptin and leptin receptors, a finding implicating paracrine or autocrine immunomodulatory 
effects of leptin on mast cells (Taildeman et al., 2009). Locally released leptin from T 
lymphocytes doesn’t seem to play a major role in immunoregulation in mouse models of 
intestinal inflammation, suggesting other sources of leptin as critical in modulation of the 
inflammatory response (Fantuzzi et al., 2005). Despite evidence supporting the role of leptin 
in immune processes (Lago et al., 2008; Matarese et al., 2005), its precise role in inflammation 
remains incompletely understood.  
7. Oxidative stress and prematurity 
A variety of events associated with poor fetal growth or preterm birth are also associated 
with oxidative stress. These include maternal infection and inflammation that lead to 
increased lipid peroxidation, but more importantly to alterations in the expression of many 
genes associated with adverse perinatal outcomes (Ingelfinger, 2007).   
Considerable evidence indicates that oxidative stress may be increased in patients with 
ASD, possibly due to their decreased ability to neutralize free radicals. An earlier study 
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showed increased levels of plasma malondialdehyde, a marker of oxidative stress, (p<0.05) 
in the blood of mothers who delivered preterm and in the cord blood of their preterm 
neonates, compared to the levels in samples from term deliveries (Joshi et al., 2008). Preterm 
birth is associated with increased generation of reactive oxygen species (ROS), which places 
these infants in high risk for injury (Davis & Auten, 2010). In fact, a recent study identified 
an increase in the oxidative stress marker non-protein bound iron (NPBI) in the cord blood 
of 168 preterm newborns of gestational age 24-32 weeks (Perrone et al., 2010), suggesting 
that early identification of neonates at-risk is possible. 
The impact of environmental oxidants in the etiology of autism is associated with brain 
region-specific changes in oxidative stress markers, such as 3-nitrotyrosine (3-NT) and 
neurotrophin-3 (NT-3), in ASD (Sajdel-Sulkowska et al., 2008; Sajdel-Sulkowska et al., 2011). 
Deficiencies in anti-oxidant enzymes might, in certain cases, be associated with mercury 
toxicity, which was shown to be tightly bound to and inactivate thioredoxin (Carvalho et al., 
2008). In fact, cytosolic and mitochondrial redox imbalance was found in lymphoblastoid 
cells of ASD children compared to controls, an event exaggerated by exposure to thimerosal 
(James et al., 2009).  
Several studies have suggested a link between oxidative stress and the immune response 
(Viora et al., 2001). Because immune cell functions are specially linked to ROS generation, 
their normal functioning is largely dependent on the oxidant/antioxidant balance. A strong 
association between oxidative stress and autoimmunity was shown in a group of 44 
Egyptian autistic children, 88.64% of whom had elevated plasma F2-isoprostane (a marker 
of lipid peroxidation) and/or reduced glutathione peroxidase (an anti-oxidant enzyme), 
compared to 44 age-matched controls. Anti-neuronal antibodies were found in 54.5% of the 
same cohort, implying immunomodulation (Mostafa et al., 2010). Several groups have 
hypothesized that oxidative stress is the mechanism by which prenatal LPS affects offspring 
neurodevelopment (Lante et al., 2008; Paintlia et al., 2008). Potential therapies for oxidative 
stress and ROS-induced morbidities in the preterm infant include both enzymatic and 
nonenzymatic antioxidant preparations (Lee & Davis, 2011), such as the naturally-occuring 
flavonoids quercetin and luteolin (Cotelle, 2001; Middleton, Jr. et al., 2000). Quercetin 
inhibits mast cells (Kandere-Grzybowska et al., 2006), and also inhibited and reversed acute 
stress-induced autistic-like behavior and the associated reduced brain glutathione levels in 
mice (Kumar & Goyal, 2008). Luteolin can also block mast cell activation and 
superstimulation of activated T-cells (Kempuraj et al., 2008; Theoharides et al., 2007a). 
Luteolin and its structural analog diosmin prevented MIA-induced behavioral deficits in the 
mouse offspring by blocking the IL-6-induced JAK2/STAT3 (Janus tyrosine kinase-2/signal 
transducer and activator of transcription-3) signaling pathway, both in vivo and in vitro 
(Parker-Athill et al., 2009). A luteolin-containing dietary supplement, Neuroprotek® was 
recently made available to help the body reduce brain inflammation. 
8. Conclusion 
A number of findings suggest the presence of different biological endophenotypes in ASD 
(Persico et al., 2008), as well as  between early-onset and regressive autism, with the latter 
being associated with poorer outcomes in social reciprocity, verbal IQ and more 
gastrointestinal symptoms, according to caregiver interviews (Richler et al., 2006). 
Increasing evidence indicates that perinatal immune activation, in the mother and/or the 
fetus, could adversely affect neurodevelopment. Moreover, mast cell activation during this 
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period by environmental, infectious, neurohormonal and immune triggers appears to be 
involved in gut-blood-brain barrier disruption and subsequent brain inflammation. 
Reduction of stress during gestation and infancy, potential use of specific CRH receptor 
antagonists, as well as drugs that could prevent BBB disruption, or block brain 
inflammation may prove useful in at least a subgroup of infants at high risk for developing 
autism.  These goals may be at least partly achieved by the use of mast cell blockers. 
Unfortunately, there are no clinically effective mast cell inhibitors, and the available 
disodium cromoglycate (cromolyn) has proven a weak inhibitor of human mast cells 
(Theoharides & Kalogeromitros, 2006). Instead, flavonoids such as luteolin are anti-
inflammatory and neuroprotective (Dirscherl et al., 2010), and can inhibit mast cell 
activation (Asadi et al., 2010).  
9. Acknowledgements - disclosures 
Aspects of research mentioned here were funded by Safe Minds, the National Autism 
Association, the Autism Research Collaborative, as well as Theta Biomedical Consulting and 
Development Co., Inc. (Brookline, MA). Asimenia Angelidou and Konstantinos-Dionysios 
Alysandratos are recipients of scholarships for postgraduate studies from the Hellenic State 
Scholarships Foundation (Athens, Greece). The authors declare that they have no competing 
interests. TCT is the inventor of patent application US 12/534,571; US 12/861,152; US 
13/009,282  covering the diagnosis and treatment of ASD. 
10. References 
Abbott, N. J. 2000. Inflammatory mediators and modulation of blood-brain barrier 
permeability. Cell Mol Neurobiol, 20, 131-147. 
Adams-Chapman, I. 2006. Neurodevelopmental outcome of the late preterm infant. Clin 
Perinatol., 33, 4, pp. 947-964. 
Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A., Lykouras 
L, Kalogeromitros D, & Theoharides TC. 2010. Neurotensin is increased in serum of 
young children with autistic disorder. J Neuroinflammation, 7, 48. 
Angelidou, A., Alysandratos, K. D., Asadi, S., Zhang, B., Francis, K., Vasiadi, M., 
Kalogeromitros, D., & Theoharides, T. C. 2011. Brief Report: "Allergic Symptoms" in 
Children with Autism Spectrum Disorders. More than Meets the Eye? J Autism 
Dev.Disord., (Jan 6) [Ahead of print]. 
Angioni, S., Petraglia, F., Gallinelli, A., Cossarizza, A., Franceschi, C., Muscettola, M., 
Genazzani, A. D., Surico, N., & Genazzani, A. R. 1993. Corticotropin-releasing 
hormone modulates cytokines release in cultured human peripheral blood 
mononuclear cells. Life Sci, 53, 1735-1742. 
Argyropoulou, M. I. 2010. Brain lesions in preterm infants: initial diagnosis and follow-up. 
Pediatr Radiol., 40, 6, pp. 811-818. 
Asadi, S., Zhang, B., Weng, Z., Angelidou, A., Kempuraj, D., Alysandratos, K. D., & 
Theoharides, T. C. 2010. Luteolin and thiosalicylate inhibit HgCl2 and thimerosal-
induced VEGF release from human mast cells. Int J Immunopathol.Pharmacol, 23, 4, 
pp. 1015-1020. 
Ashwood, P., Anthony, A., Pellicer, A. A., Torrente, F., Walker-Smith, J. A., & Wakefield, A. 
J. 2003. Intestinal lymphocyte populations in children with regressive autism: 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
277 
evidence for extensive mucosal immunopathology. J Clin Immunol., 23, 6, pp. 504-
517. 
Ashwood, P., Enstrom, A., Krakowiak, P., Hertz-Picciotto, I., Hansen, R. L., Croen, L. A., 
Ozonoff, S., Pessah, I. N., & de Water, J. V. 2008. Decreased transforming growth 
factor beta1 in autism: A potential link between immune dysregulation and 
impairment in clinical behavioral outcomes. J Neuroimmunol., 204, 149-153. 
Ashwood, P., Kwong, C., Hansen, R., Hertz-Picciotto, I., Croen, L., Krakowiak, P., Walker, 
W., Pessah, I. N., & Van de, Water J. 2007. Brief Report: Plasma leptin levels are 
elevated in autism: Association with early onset phenotype? J.Autism Dev.Disord., 
38, 1, pp. 169-175. 
Atladottir, H. O., Pedersen, M. G., Thorsen, P., Mortensen, P. B., Deleuran, B., Eaton, W. W., 
& Parner, E. T. 2009. Association of family history of autoimmune diseases and 
autism spectrum disorders. Pediatrics, 124, 2, pp. 687-694. 
Atladottir, H. O., Thorsen, P., Ostergaard, L., Schendel, D. E., Lemcke, S., Abdallah, M., & 
Parner, E. T. 2010. Maternal infection requiring hospitalization during pregnancy 
and autism spectrum disorders. J Autism Dev.Disord., 40, 12, pp. 1423-1430. 
Beversdorf, D. Q., Manning, S. E., Hillier, A., Anderson, S. L., Nordgren, R. E., Walters, S. E., 
Nagaraja, H. N., Cooley, W. C., Gaelic, S. E., & Bauman, M. L. 2005. Timing of 
prenatal stressors and autism. J Autism Dev.Disord., 35, 4, pp. 471-478. 
Blank, U.,Rivera, J. 2004. The ins and outs of IgE-dependent mast-cell exocytosis. Trends 
Immunol, 25, 266-273. 
Blardi, P., de, Lalla A., Ceccatelli, L., Vanessa, G., Auteri, A., & Hayek, J. 2010. Variations of 
plasma leptin and adiponectin levels in autistic patients. Neurosci.Lett., 479, 1, pp. 
54-57. 
Blardi, P., de, Lalla A., D'Ambrogio, T., G V, L C, A A, & J H. 2008. Long-term plasma levels 
of leptin and adiponectin in Rett Syndrome. Clin Endocrinol.(Oxf), 70, 5, pp. 706-709. 
Boksa, P. 2010. Effects of prenatal infection on brain development and behavior: a review of 
findings from animal models. Brain Behav.Immun., 24, 6, pp. 881-897. 
Braunschweig, D., Ashwood, P., Krakowiak, P., Hertz-Picciotto, I., Hansen, R., Croen, L. A., 
Pessah, I. N., & Van de Water J. 2008. Autism: maternally derived antibodies 
specific for fetal brain proteins. NeuroToxicology, 29, 2, pp. 226-231. 
Brimacombe, M., Ming, X., & Lamendola, M. 2007. Prenatal and birth complications in 
autism. Matern.Child Health J, 11, 1, pp. 73-79. 
Buchmayer, S., Johansson, S., Johansson, A., Hultman, C. M., Sparen, P., & Cnattingius, S. 
2009. Can association between preterm birth and autism be explained by maternal 
or neonatal morbidity? Pediatrics, 124, 5, pp. e817-e825. 
Buie, T., Campbell, D. B., Fuchs, G. J., III, Furuta, G. T., Levy, J., Vandewater, J., Whitaker, A. 
H., Atkins, D., Bauman, M. L., Beaudet, A. L., Carr, E. G., Gershon, M. D., Hyman, 
S. L., Jirapinyo, P., Jyonouchi, H., Kooros, K., Kushak, R., Levitt, P., Levy, S. E., 
Lewis, J. D., Murray, K. F., Natowicz, M. R., Sabra, A., Wershil, B. K., Weston, S. C., 
Zeltzer, L., & Winter, H. 2010. Evaluation, diagnosis, and treatment of 
gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics, 
125, Suppl 1:S1-18. 
Cabanlit, M., Wills, S., Goines, P., Ashwood, P., & Van de Water, J. 2007. Brain-specific 
autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann.N 
Y.Acad.Sci., 1107, 92-103. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
278 
Campbell, E. A., Linton, E. A., Wolfe, C. D., Scraggs, P. R., Jones, M. T., & Lowry, P. J. 1987. 
Plasma corticotropin-releasing hormone concentrations during pregnancy and 
parturition. J Clin Endocrinol.Metab, 64, 5, pp. 1054-1059. 
Cao, J., Papadopoulou, N., Kempuraj, D., Boucher, W. S., Sugimoto, K, Cetrulo, C. L., & 
Theoharides, T. C. 2005. Human mast cells express corticotropin-releasing hormone 
(CRH) receptors and CRH leads to selective secretion of vascular endothelial 
growth factor. J Immunol, 174, 7665-7675. 
Carvalho, C. M., Chew, E. H., Hashemy, S. I., Lu, J., & Holmgren, A. 2008. Inhibition of the 
human thioredoxin system. A molecular mechanism of mercury toxicity. J 
Biol.Chem., 283, 18, pp. 11913-11923. 
Castagliuolo, I., Leeman, S. E., Bartolac-Suki, E., Nikulasson, S., Qiu, B., Carraway, R. E., & 
Pothoulakis, C. 1996. A neurotensin antagonist, SR 48692, inhibits colonic responses 
to immobilization stress in rats. Proc Natl Acad Sci USA, 93, 12611-12615. 
Chandler, N., Jacobson, S., Connolly, R., Esposito, P., & Theoharides, T. C. 2002. Acute stress 
shortens the time of onset of experimental allergic encephalomyelitis (EAE) in 
SJL/J mice. Brain Behav Immun, 16, 757-763. 
Chandra, R. K. 1980. Cell-mediated immunity in genetically obese C57BL/6J ob/ob) mice. 
Am.J Clin Nutr., 33, 1, pp. 13-16. 
Cheslack-Postava, K., Liu, K., & Bearman, P. S. 2011. Closely Spaced Pregnancies Are 
Associated With Increased Odds of Autism in California Sibling Births. Pediatrics,  
Chess, S. 1977. Follow-up report on autism in congenital rubella. J Autism Child Schizophr., 7, 
1, pp. 69-81. 
Chez, M. G., Dowling, T., Patel, P. B., Khanna, P., & Kominsky, M. 2007. Elevation of tumor 
necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr.Neurol., 36, 6, 
pp. 361-365. 
Chrousos, G. P. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated 
inflammation. N Engl J Med, 332, 1351-1362. 
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., 
Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., & . 1996. Serum 
immunoreactive-leptin concentrations in normal-weight and obese humans. 
N.Engl.J Med., 334, 5, pp. 292-295. 
Conti, P., Pang, X., Boucher, W., Letourneau, R., Reale, M., Barbacane, R. C., Thibault, J., & 
Theoharides, T. C. 1997. Impact of Rantes and MCP-1 chemokines on in vivo 
basophilic mast cell recruitment in rat skin injection model and their role in 
modifying the protein and mRNA levels for histidine decarboxylase. Blood, 89, 
4120-4127. 
Corbett, B. A., Schupp, C. W., Levine, S., & Mendoza, S. 2009. Comparing cortisol, stress, 
and sensory sensitivity in children with autism. Autism Res., 2, 1, pp. 39-49. 
Corbett, B. A., Schupp, C. W., Simon, D., Ryan, N., & Mendoza, S. 2010. Elevated cortisol 
during play is associated with age and social engagement in children with autism. 
Mol.Autism, 1, 1, pp. 13. 
Cotelle, N. 2001. Role of flavonoids in oxidative stress. Curr.Top.Med.Chem., 1, 6, pp. 569-590. 
Croen, L. A., Braunschweig, D., Haapanen, L., Yoshida, C. K., Fireman, B., Grether, J. K., 
Kharrazi, M., Hansen, R. L., Ashwood, P., & Van de, Water J. 2008. Maternal mid-
pregnancy autoantibodies to fetal brain protein: the early markers for autism study. 
Biological Psychiatry, 64, 7, pp. 583-588. 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
279 
Croen, L. A., Grether, J. K., Yoshida, C. K., Odouli, R., & Van de, Water J. 2005. Maternal 
autoimmune diseases, asthma and allergies, and childhood autism spectrum 
disorders: a case-control study. Arch.Pediatr.Adolesc.Med., 159, 2, pp. 151-157. 
Dardeno, T. A., Chou, S. H., Moon, H. S., Chamberland, J. P., Fiorenza, C. G., & Mantzoros, 
C. S. 2010. Leptin in human physiology and therapeutics. Front Neuroendocrinol., 31, 
3, pp. 377-393. 
Davis, J. M.,Auten, R. L. 2010. Maturation of the antioxidant system and the effects on 
preterm birth. Semin.Fetal Neonatal Med., 15, 4, pp. 191-195. 
Deth, R., Muratore, C., Benzecry, J., Power-Charnitsky, V. A., & Waly, M. 2008. How 
environmental and genetic factors combine to cause autism: A redox/methylation 
hypothesis. NeuroToxicology, 29, 1, pp. 190-201. 
Dirscherl, K., Karlstetter, M., Ebert, S., Kraus, D., Hlawatsch, J., Walczak, Y., Moehle, C., 
Fuchshofer, R., & Langmann, T. 2010. Luteolin triggers global changes in the 
microglial transcriptome leading to a unique anti-inflammatory and 
neuroprotective phenotype. J Neuroinflammation., 7, 1, pp. 3. 
Dodds, L., Fell, D. B., Shea, S., Armson, B. A., Allen, A. C., & Bryson, S. 2010. The Role of 
Prenatal, Obstetric and Neonatal Factors in the Development of Autism. J Autism 
Dev.Disord.,  
Dommergues, M. A., Patkai, J., Renauld, J. C., Evrard, P., & Gressens, P. 2000. 
Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the 
newborn murine neopallium. Ann.Neurol., 47, 1, pp. 54-63. 
Donelan, J., Boucher, W., Papadopoulou, N., Lytinas, M., Papaliodis, D., & Theoharides, T. 
C. 2006. Corticotropin-releasing hormone induces skin vascular permeability 
through a neurotensin-dependent process. Proc Natl Acad Sci USA, 103, 7759-7764. 
Drube, S., Heink, S., Walter, S., Lohn, T., Grusser, M., Gerbaulet, A., Berod, L., Schons, J., 
Dudeck, A., Freitag, J., Grotha, S., Reich, D., Rudeschko, O., Norgauer, J., 
Hartmann, K., Roers, A., & Kamradt, T. 2010. The receptor tyrosine kinase c-Kit 
controls IL-33 receptor signaling in mast cells. Blood, 115, 19, pp. 3899-3906. 
Dubicke, A., Fransson, E., Centini, G., Andersson, E., Bystrom, B., Malmstrom, A., Petraglia, 
F., Sverremark-Ekstrom, E., & Ekman-Ordeberg, G. 2010. Pro-inflammatory and 
anti-inflammatory cytokines in human preterm and term cervical ripening. J 
Reprod.Immunol, 84, 2, pp. 176-185. 
Dunn, S. J., Greenberg, H. B., Ward, R. L., Nakagomi, O., Burns, J. W., Vo, P. T., Pax, K. A., 
Das, M., Gowda, K., & Rao, C. D. 1993. Serotypic and genotypic characterization of 
human serotype 10 rotaviruses from asymptomatic neonates. J Clin Microbiol., 31, 1, 
pp. 165-169. 
Durkin, M. S., Maenner, M. J., Meaney, F. J., Levy, S. E., DiGuiseppi, C., Nicholas, J. S., 
Kirby, R. S., Pinto-Martin, J. A., & Schieve, L. A. 2010. Socioeconomic inequality in 
the prevalence of autism spectrum disorder: evidence from a U.S. cross-sectional 
study. PLoS.ONE., 5, 7, pp. e11551. 
Ehninger, D., Sano, Y., de Vries, P. J., Dies, K., Franz, D., Geschwind, D. H., Kaur, M., Lee, Y. 
S., Li, W., Lowe, J. K., Nakagawa, J. A., Sahin, M., Smith, K., Whittemore, V., & 
Silva, A. J. 2010. Gestational immune activation and Tsc2 haploinsufficiency 
cooperate to disrupt fetal survival and may perturb social behavior in adult mice. 
Mol.Psychiatry, (Nov 16) [Ahead of print]. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
280 
Enstrom, A. M., Van de Water, J. A., & Ashwood, P. 2009. Autoimmunity in autism. 
Curr.Opin.Investig.Drugs, 10, 5, pp. 463-473. 
Esposito, P., Chandler, N., Kandere-Grzybowska, K, Basu, S., Jacobson, S., Connolly, R., 
Tutor, D., & Theoharides, T. C. 2002. Corticotropin-releasing hormone (CRH) and 
brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J 
Pharmacol Exp Ther, 303, 1061-1066. 
Esposito, P., Gheorghe, D., Kandere, K., Pang, X., Conally, R., Jacobson, S., & Theoharides, T. 
C. 2001. Acute stress increases permeability of the blood-brain-barrier through 
activation of brain mast cells. Brain Res, 888, 117-127. 
Fantuzzi, G., Sennello, J. A., Batra, A., Fedke, I., Lehr, H. A., Zeitz, M., & Siegmund, B. 2005. 
Defining the role of T cell-derived leptin in the modulation of hepatic or intestinal 
inflammation in mice. Clin Exp.Immunol, 142, 1, pp. 31-38. 
Fombonne, E. 2009. Epidemiology of pervasive developmental disorders. Pediatric Research, 
65, 6, pp. 591-598. 
Forbes, E. E., Groschwitz, K., Abonia, J. P., Brandt, E. B., Cohen, E., Blanchard, C., Ahrens, 
R., Seidu, L., McKenzie, A., Strait, R., Finkelman, F. D., Foster, P. S., Matthaei, K. I., 
Rothenberg, M. E., & Hogan, S. P. 2008. IL-9- and mast cell-mediated intestinal 
permeability predisposes to oral antigen hypersensitivity. Journal of Experimental 
Medicine, 205, 4, pp. 897-913. 
Galli, S. J., Kalesnikoff, J., Grimbaldeston, M. A., Piliponsky, A. M., Williams, C. M., & Tsai, 
M. 2005. Mast cells as "tunable" effector and immunoregulatory cells: recent 
advances. Annu Rev Immunol, 23, 749-786. 
Gardener, H., Spiegelman, D., & Buka, S. L. 2009. Prenatal risk factors for autism: 
comprehensive meta-analysis. Br.J Psychiatry, 195, 1, pp. 7-14. 
Gebhardt, T., Lorentz, A., Detmer, F., Trautwein, C., Bektas, H., Manns, M. P., & Bischoff, S. 
C. 2005. Growth, phenotype, and function of human intestinal mast cells are tightly 
regulated by transforming growth factor beta1. Gut, 54, 7, pp. 928-934. 
Gillott, A.,Standen, P. J. 2007. Levels of anxiety and sources of stress in adults with autism. 
J.Intellect.Disabil., 11, 4, pp. 359-370. 
Girard, S., Tremblay, L., Lepage, M., & Sebire, G. 2010. IL-1 receptor antagonist protects 
against placental and neurodevelopmental defects induced by maternal 
inflammation. J Immunol, 184, 7, pp. 3997-4005. 
Giulivi, C., Zhang, Y. F., Omanska-Klusek, A., Ross-Inta, C., Wong, S., Hertz-Picciotto, I., 
Tassone, F., & Pessah, I. N. 2010. Mitochondrial dysfunction in autism. JAMA, 304, 
21, pp. 2389-2396. 
Glasson, E. J., Bower, C., Petterson, B., de, Klerk N., Chaney, G., & Hallmayer, J. F. 2004. 
Perinatal factors and the development of autism: a population study. 
Arch.Gen.Psychiatry, 61, 6, pp. 618-627. 
Gluckman, P. D., Lillycrop, K. A., Vickers, M. H., Pleasants, A. B., Phillips, E. S., Beedle, A. 
S., Burdge, G. C., & Hanson, M. A. 2007. Metabolic plasticity during mammalian 
development is directionally dependent on early nutritional status. Proc Natl Acad 
Sci U S A, 104, 31, pp. 12796-12800. 
Goines, P.,Van de Water J. 2010. The immune system's role in the biology of autism. 
Curr.Opin.Neurol., 23, 2, pp. 111-117. 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
281 
Grammatopoulos, D. K. 2008. Placental corticotrophin-releasing hormone and its receptors 
in human pregnancy and labour: still a scientific enigma. Journal of 
Neuroendocrinology, 20, 4, pp. 432-438. 
Grandjean, P.,Landrigan, P. J. 2006. Developmental neurotoxicity of industrial chemicals. 
Lancet, 368, 9553, pp. 2167-2178. 
Hauguel-de, Mouzon S., Lepercq, J., & Catalano, P. 2006. The known and unknown of leptin 
in pregnancy. Am.J Obstet.Gynecol., 194, 6, pp. 1537-1545. 
Herbert, M. R. 2010. Contributions of the environment and environmentally vulnerable 
physiology to autism spectrum disorders. Curr.Opin.Neurol., 23, 2, pp. 103-110. 
Hertz-Picciotto, I., Park, H. Y., Dostal, M., Kocan, A., Trnovec, T., & Sram, R. 2008. Prenatal 
exposures to persistent and non-persistent organic compounds and effects on 
immune system development. Basic Clin.Pharmacol.Toxicol., 102, 2, pp. 146-154. 
Ingelfinger, J. R. 2007. Prematurity and the legacy of intrauterine stress. N.Engl.J Med., 356, 
20, pp. 2093-2095. 
Ito, N., Sugawara, K., Bodo, E., Takigawa, M., van, Beek N., Ito, T., & Paus, R. 2010. 
Corticotropin-releasing hormone stimulates the in situ generation of mast cells 
from precursors in the human hair follicle mesenchyme. J Invest Dermatol., 130, 4, 
pp. 995-1004. 
James, S. J., Rose.S., Melnyk, S., Jernigan, S., Blossom, S., Pavliv, O., & Gsylor, D. W. 2009. 
Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells 
derived from children with autism. FASEB, 23(8) pp. 2374-2383. 
Johnson, C. P.,Myers, S. M. 2007. Identification and evaluation of children with autism 
spectrum disorders. Pediatrics, 120, 5, pp. 1183-1215. 
Johnson, S., Hollis, C., Kochhar, P., Hennessy, E., Wolke, D., & Marlow, N. 2010. Autism 
spectrum disorders in extremely preterm children. J Pediatr., 156, 4, pp. 525-531. 
Johnson, S.,Marlow, N. 2011. Preterm Birth and Childhood Psychiatric Disorders. Pediatric 
Research, (May) [Ahead of print]. , 69, 5 Pt 2, pp. 11R-8R 
Joshi, S. R., Mehendale, S. S., Dangat, K. D., Kilari, A. S., Yadav, H. R., & Taralekar, V. S. 
2008. High maternal plasma antioxidant concentrations associated with preterm 
delivery. Ann.Nutr.Metab, 53, 3-4, pp. 276-282. 
Kaindl, A. M., Favrais, G., & Gressens, P. 2009. Molecular mechanisms involved in injury to 
the preterm brain. J Child Neurol., 24, 9, pp. 1112-1118. 
Kalantaridou, S., Makrigiannakis, A., Zoumakis, E., & Chrousos, G. P. 2007. Peripheral 
corticotropin-releasing hormone is produced in the immune and reproductive 
systems: actions, potential roles and clinical implications. Front Biosci., 12, 572-580. 
Kandere-Grzybowska, K, Letourneau, R., Kempuraj, D., Donelan, J., Poplawski, S., Boucher, 
W., Athanassiou, A., & Theoharides, T. C. 2003. IL-1 induces vesicular secretion of 
IL-6 without degranulation from human mast cells. J Immunol, 171, 9, pp. 4830-4836. 
Kandere-Grzybowska, K., Kempuraj, D., Cao, J., Cetrulo, C. L., & Theoharides, T. C. 2006. 
Regulation of IL-1-induced selective IL-6 release from human mast cells and 
inhibition by quercetin. Br J Pharmacol, 148, 208-215. 
Karalis, K., Louis, J. M., Bae, D., Hilderbrand, H., & Majzoub, J. A. 1997. CRH and the 
immune system. J Neuroimmunol, 72, 131-136. 
Keil, A., Daniels, J. L., Forssen, U., Hultman, C., Cnattingius, S., Soderberg, K. C., Feychting, 
M., & Sparen, P. 2010. Parental autoimmune diseases associated with autism 
spectrum disorders in offspring. Epidemiology, 21, 6, pp. 805-808. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
282 
Kempuraj, D., Asadi, S., Zhang, B., Manola, A., Hogan, J., Peterson, E., & Theoharides, T. C. 
2010. Mercury induces inflammatory mediator release from human mast cells. J 
Neuroinflammation, 7, 1, pp. 20. 
Kempuraj, D., Papadopoulou, N. G., Lytinas, M., Huang, M., Kandere-Grzybowska, K., 
Madhappan, B., Boucher, W., Christodoulou, S., Athanassiou, A., & Theoharides, T. 
C. 2004. Corticotropin-releasing hormone and its structurally related urocortin are 
synthesized and secreted by human mast cells. Endocrinology, 145, 43-48. 
Kempuraj, D., Tagen, M., Iliopoulou, B. P., Clemons, A., Vasiadi, M., Boucher, W., House, 
M., Wolferg, A., & Theoharides, T. C. 2008. Luteolin inhibits myelin basic protein-
induced human mast cell activation and mast cell dependent stimulation of Jurkat 
T cells. Br J Pharmacol, 155, 1076-1084. 
Kinney, D. K., Munir, K. M., Crowley, D. J., & Miller, A. M. 2008. Prenatal stress and risk for 
autism. Neurosci.Biobehav.Rev., 32, 8, pp. 1519-1532. 
Kleinman, J. M., Robins, D. L., Ventola, P. E., Pandey, J., Boorstein, H. C., Esser, E. L., 
Wilson, L. B., Rosenthal, M. A., Sutera, S., Verbalis, A. D., Barton, M., Hodgson, S., 
Green, J., Dumont-Mathieu, T., Volkmar, F., Chawarska, K., Klin, A., & Fein, D. 
2008. The modified checklist for autism in toddlers: a follow-up study investigating 
the early detection of autism spectrum disorders. J Autism Dev.Disord., 38, 5, pp. 
827-839. 
Kogan, M. D., Blumberg, S. J., Schieve, L. A., Boyle, C. A., Perrin, J. M., Ghandour, R. M., 
Singh, G. K., Strickland, B. B., Trevathan, E., & van Dyck, P. C. 2009. Prevalence of 
parent-reported diagnosis of autism spectrum disorder among children in the US, 
2007. Pediatrics, 5, 124, pp. 1395-1403. 
Kraft, S.,Kinet, J. P. 2007. New developments in FcepsilonRI regulation, function and 
inhibition. Nat Rev.Immunol, 7, 5, pp. 365-378. 
Kuban, K. C., O'Shea, T. M., Allred, E. N., Tager-Flusberg, H., Goldstein, D. J., & Leviton, A. 
2009. Positive screening on the Modified Checklist for Autism in Toddlers (M-
CHAT) in extremely low gestational age newborns. Journal of Pediatrics, 154, 4, pp. 
535-540. 
Kulka, M., Alexopoulou, L., Flavell, R. A., & Metcalfe, D. D. 2004. Activation of mast cells by 
double-stranded RNA: evidence for activation through Toll-like receptor 3. J Allergy 
Clin.Immunol, 114, 1, pp. 174-182. 
Kumar, A.,Goyal, R. 2008. Quercetin protects against acute immobilization stress-induced 
behaviors and biochemical alterations in mice. J Med Food, 11, 3, pp. 469-473. 
Kwon, O., Lee, E., Moon, T. C., Jung, H., Lin, C. X., Nam, K. S., Baek, S. H., Min, H. K., & 
Chang, H. W. 2002. Expression of cyclooxygenase-2 and pro-inflammatory 
cytokines induced by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) in human mast 
cells requires NF-kappa B activation. Biol.Pharm.Bull., 25, 9, pp. 1165-1168. 
Lago, R., Gomez, R., Lago, F., Gomez-Reino, J., & Gualillo, O. 2008. Leptin beyond body 
weight regulation--current concepts concerning its role in immune function and 
inflammation. Cell Immunol, 252, 1-2, pp. 139-145. 
Lante, F., Meunier, J., Guiramand, J., De Jesus Ferreira, M. C., Cambonie, G., Aimar, R., 
Cohen-Solal, C., Maurice, T., Vignes, M., & Barbanel, G. 2008. Late N-acetylcysteine 
treatment prevents the deficits induced in the offspring of dams exposed to an 
immune stress during gestation. Hippocampus, 18, 6, pp. 602-609. 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
283 
Larsson, H. J., Eaton, W. W., Madsen, K. M., Vestergaard, M., Olesen, A. V., Agerbo, E., 
Schendel, D., Thorsen, P., & Mortensen, P. B. 2005. Risk factors for autism: perinatal 
factors, parental psychiatric history, and socioeconomic status. Am.J Epidemiol., 161, 
10, pp. 916-925. 
Lee, J. W.,Davis, J. M. 2011. Future applications of antioxidants in premature infants. 
Curr.Opin.Pediatr., 23, 2, pp. 161-166. 
Lee, J. Y., Huerta, P. T., Zhang, J., Kowal, C., Bertini, E., Volpe, B. T., & Diamond, B. 2009. 
Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in 
maternal lupus. Nat.Med., 15, 1, pp. 91-96. 
Levy, S. E., Mandell, D. S., & Schultz, R. T. 2009. Autism. Lancet, 374, 9701, pp. 1627-1638. 
Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X. M., Ji, L., Brown, T., & Malik, 
M. 2009. Elevated immune response in the brain of autistic patients. 
J.Neuroimmunol., 207, 1-2, pp. 111-116. 
Libbey, J. E., Sweeten, T. L., McMahon, W. M., & Fujinami, R. S. 2005. Autistic disorder and 
viral infections. J Neurovirol., 11, 1, pp. 1-10. 
Limperopoulos, C. 2009. Autism spectrum disorders in survivors of extreme prematurity. 
Clin Perinatol., 36, 4, pp. 791-805, vi. 
Limperopoulos, C., Bassan, H., Gauvreau, K., Robertson, R. L., Jr., Sullivan, N. R., Benson, C. 
B., Avery, L., Stewart, J., Soul, J. S., Ringer, S. A., Volpe, J. J., & duPlessis, A. J. 2007. 
Does cerebellar injury in premature infants contribute to the high prevalence of 
long-term cognitive, learning, and behavioral disability in survivors? Pediatrics, 120, 
3, pp. 584-593. 
Limperopoulos, C., Bassan, H., Sullivan, N. R., Soul, J. S., Robertson, R. L., Jr., Moore, M., 
Ringer, S. A., Volpe, J. J., & du Plessis, A. J. 2008. Positive screening for autism in 
ex-preterm infants: prevalence and risk factors. Pediatrics, 121, 4, pp. 758-765. 
Lin, C. Y., Chang, Y. C., Wang, S. T., Lee, T. Y., Lin, C. F., & Huang, C. C. 2010. Altered 
inflammatory responses in preterm children with cerebral palsy. Ann.Neurol., 68, 2, 
pp. 204-212. 
MacDorman, M. F., Declercq, E., & Zhang, J. 2010. Obstetrical intervention and the singleton 
preterm birth rate in the United States from 1991-2006. Am J Public Health, 100, 11, 
pp. 2241-2247. 
Maimburg, R. D.,Vaeth, M. 2006. Perinatal risk factors and infantile autism. Acta 
Psychiatr.Scand., 114, 4, pp. 257-264. 
Makrigiannakis, A., Semmler, M., Briese, V., Eckerle, H., Minas, V., Mylonas, I., Friese, K., & 
Jeschke, U. 2007. Maternal serum corticotropin-releasing hormone and ACTH 
levels as predictive markers of premature labor. Int.J.Gynaecol.Obstet., 97, 2, pp. 115-
119. 
Martin, J. A. 2011. Preterm Births --- United States, 2007. MMWR Surveill Summ., 60, SU-1, 
pp. 78-79. 
Matarese, G., Moschos, S., & Mantzoros, C. S. 2005. Leptin in immunology. J Immunol, 174, 6, 
pp. 3137-3142. 
Matson J.L.,Kozlowski A.M. 2010. Autistic regression. Res Autism Spectr Disord, 4, 340-345. 
Middleton, E, Jr., Kandaswami, C., & Theoharides, T. C. 2000. The effects of plant flavonoids 
on mammalian cells: implications for inflammation, heart disease and cancer. 
Pharmacol Rev, 52, 673-751. 
Miles, J. H. 2011. Autism spectrum disorders-A genetics review. Genet.Med, 13(4):278-294. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
284 
Minagar, A.,Alexander, J. S. 2003. Blood-brain barrier disruption in multiple sclerosis. 
Mult.Scler., 9, 6, pp. 540-549. 
Money, J., Bobrow, N. A., & Clarke, F. C. 1971. Autism and autoimmune disease: a family 
study. J Autism Child Schizophr., 1, 2, pp. 146-160. 
Mostafa, G. A., El-Hadidi, E. S., Hewedi, D. H., & Abdou, M. M. 2010. Oxidative stress in 
Egyptian children with autism: relation to autoimmunity. J Neuroimmunol., 219, 1-2, 
pp. 114-118. 
Mostafa, G. A., El-Sayed, Z. A., El-Aziz, M. M., & El-Sayed, M. F. 2008. Serum anti-myelin-
associated glycoprotein antibodies in Egyptian autistic children. J Child Neurol, 23, 
12, pp. 1413-1418. 
Mostafa, G. A.,Kitchener, N. 2009. Serum anti-nuclear antibodies as a marker of 
autoimmunity in Egyptian autistic children. Pediatr Neurol, 40, 2, pp. 107-112. 
O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A. M., Quigley, E. M., 
Cryan, J. F., & Dinan, T. G. 2009. Early life stress alters behavior, immunity, and 
microbiota in rats: implications for irritable bowel syndrome and psychiatric 
illnesses. Biological Psychiatry, 65, 3, pp. 263-267. 
Okumura, A., Yamamoto, T., Kidokoro, H., Kato, T., Kubota, T., Shoji, H., Sato, H., 
Shimojima, K., & Shimizu, T. 2010. Altered gene expression in umbilical cord 
mononuclear cells in preterm infants with periventricular leukomalacia. Early 
Hum.Dev., 86, 10, pp. 665-667. 
Paintlia, M. K., Paintlia, A. S., Contreras, M. A., Singh, I., & Singh, A. K. 2008. 
Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white 
matter injury: attenuation by N-acetyl cysteine. Exp.Neurol., 210, 2, pp. 560-576. 
Palmieri, L.,Persico, A. M. 2010. Mitochondrial dysfunction in autism spectrum disorders: 
Cause or effect? Biochim.Biophys.Acta, 1797, 6-7, pp. 1130-1137. 
Parker-Athill, E., Luo, D., Bailey, A., Giunta, B., Tian, J., Shytle, R. D., Murphy, T., Legradi, 
G., & Tan, J. 2009. Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 
signaling to oppose IL-6/MIA associated autism. J Neuroimmunol., 217, 1-2, pp. 20-
27. 
Perrone, S., Tataranno, M. L., Negro, S., Longini, M., Marzocchi, B., Proietti, F., Iacoponi, F., 
Capitani, S., & Buonocore, G. 2010. Early identification of the risk for free radical-
related diseases in preterm newborns. Early Hum.Dev., 86, 4, pp. 241-244. 
Persico, A. M., Sacco, R., Curatolo, P., Manzi, B., Lenti, C., Saccani, M., Militerni, R., 
Bravaccio, C., & Elia, A. 2008. Isolation of principal components in autistic disorder 
symptomatology and their association with biological endophenotypes. Proc.Society 
for Neuroscience, Washington DC, Abstract #446.20. 
Petraglia, F., Garuti, G. C., De, Ramundo B., Angioni, S., Genazzani, A. R., & Bilezikjian, L. 
M. 1990. Mechanism of action of interleukin-1 beta in increasing corticotropin-
releasing factor and adrenocorticotropin hormone release from cultured human 
placental cells. Am.J Obstet.Gynecol., 163, 4 Pt 1, pp. 1307-1312. 
Richler, J., Luyster, R., Risi, S., Hsu, W. L., Dawson, G., Bernier, R., Dunn, M., Hepburn, S., 
Hyman, S. L., McMahon, W. M., Goudie-Nice, J., Minshew, N., Rogers, S., Sigman, 
M., Spence, M. A., Goldberg, W. A., Tager-Flusberg, H., Volkmar, F. R., & Lord, C. 
2006. Is there a 'regressive phenotype' of Autism Spectrum Disorder associated 
with the measles-mumps-rubella vaccine? A CPEA Study. J Autism Dev.Disord., 36, 
3, pp. 299-316. 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
285 
Rovira, N., Alarcon, A., Iriondo, M., Ibanez, M., Poo, P., Cusi, V., Agut, T., Pertierra, A., & 
Krauel, X. 2011. Impact of histological chorioamnionitis, funisitis and clinical 
chorioamnionitis on neurodevelopmental outcome of preterm infants. Early 
Hum.Dev,  
Sajdel-Sulkowska, E. M., Lipinski, B., Windom, H., Audhya, T., & McGinnis, W. 2008. 
Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. AM J Biochem 
Biotechnol, 4, 73-84. 
Sajdel-Sulkowska, E. M., Xu, M., McGinnis, W., & Koibuchi, N. 2011. Brain region-specific 
changes in oxidative stress and neurotrophin levels in autism spectrum disorders 
(ASD). Cerebellum, 10, 1, pp. 43-48. 
Saresella, M., Marventano, I., Guerini, F. R., Mancuso, R., Ceresa, L., Zanzottera, M., 
Rusconi, B., Maggioni, E., Tinelli, C., & Clerici, M. 2009. An autistic endophenotype 
results in complex immune dysfunction in healthy siblings of autistic children. 
Biological Psychiatry, 66, 10, pp. 978-984. 
Schroeder, J. T., Kagey-Sobotka, A., MacGlashan, D. W., & Lichtenstein, L. M. 1995. The 
interaction of cytokines with human basophils and mast cells. International Archives 
of Allergy and Immunology, 107, 79-81. 
Schwartz, L. B. 1987. Mediators of human mast cells and human mast cell subsets. Ann 
Allergy, 58, 226-235. 
Serafin, W. E.,Austen, K. F. 1987. Mediators of immediate hypersensitivity reactions. N Engl 
J Med, 317, 30-34. 
Singer, H. S., Morris, C. M., Gause, C. D., Gillin, P. K., Crawford, S., & Zimmerman, A. W. 
2008. Antibodies against fetal brain in sera of mothers with autistic children. J 
Neuroimmunol., 194, 1-2, pp. 165-172. 
Singer, H. S., Morris, C. M., Williams, P. N., Yoon, D. Y., Hong, J. J., & Zimmerman, A. W. 
2006. Antibrain antibodies in children with autism and their unaffected siblings. J 
Neuroimmunol., 178, 1-2, pp. 149-155. 
Singh, V. K.,Rivas, W. H. 2004. Prevalence of serum antibodies to caudate nucleus in autistic 
children. Neurosci.Lett., 355, 1-2, pp. 53-56. 
Singh, V. K., Warren, R., Averett, R., & Ghaziuddin, M. 1997. Circulating autoantibodies to 
neuronal and glial filament proteins in autism. Pediatr.Neurol., 17, 1, pp. 88-90. 
Skofitsch, G., Zamir, N., Helke, C. J., Savitt, J. M., & Jacobowitz, D. M. 1985. Corticotropin-
releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive 
neurons of the rat central nervous system: colocalization with other neuropeptides. 
Peptides, 6, 307-318. 
Slominski, A., Wortsman, J., Pisarchik, A., Zbytek, B., Linton, E. A., Mazurkiewicz, J. E., & 
Wei, E. T. 2001. Cutaneous expression of corticotropin-releasing hormone (CRH), 
urocortin, and CRH receptors. FASEB J, 15, 1678-1693. 
Slominski, A., Zbytek, B., Zmijewski, M., Slominski, R. M., Kauser, S., Wortsman, J., & 
Tobin, D. J. 2006. Corticotropin releasing hormone and the skin. Front Biosci, 11, 
2230-2248. 
Smalley, S. L. 1998. Autism and tuberous sclerosis. J Autism Dev.Disord., 28, 5, pp. 407-414. 
Smith, S. E., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. 2007. Maternal immune 
activation alters fetal brain development through interleukin-6. Journal of 
Neuroscience, 27, 40, pp. 10695-10702. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
286 
Snegovskikh, V. V., Schatz, F., Arcuri, F., Toti, P., Kayisli, U. A., Murk, W., Guoyang, Luo, 
Lockwood, C. J., & Norwitz, E. R. 2009. Intra-amniotic infection upregulates 
decidual cell vascular endothelial growth factor (VEGF) and neuropilin-1 and -2 
expression: implications for infection-related preterm birth. Reprod.Sci., 16, 8, pp. 
767-780. 
Soderholm, J. D., Yates, D. A., Gareau, M. G., Yang, P. C., MacQueen, G., & Perdue, M. H. 
2002. Neonatal maternal separation predisposes adult rats to colonic barrier 
dysfunction in response to mild stress. Am.J Physiol Gastrointest.Liver Physiol, 283, 6, 
pp. G1257-G1263. 
Soon, D., Altmann, D. R., Fernando, K. T., Giovannoni, G., Barkhof, F., Polman, C. H., 
O'Connor, P., Gray, B., Panzara, M., & Miller, D. H. 2007. A study of subtle blood 
brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing 
remitting multiple sclerosis. J Neurol., 254, 3, pp. 306-314. 
Stein, D., Weizman, A., Ring, A., & Barak, Y. 2006. Obstetric complications in individuals 
diagnosed with autism and in healthy controls. Comprehensive Psychiatry, 47, 1, pp. 
69-75. 
Stone, K. D., Prussin, C., & Metcalfe, D. D. 2010. IgE, mast cells, basophils, and eosinophils. 
The Journal of Allergy and Clinical Immunology, 125, 2 Suppl 2, pp. S73-S80. 
Stone, L. A., Smith, M. E., Albert, P. S., Bash, C. N., Maloni, H., Frank, J. A., & McFarland, H. 
F. 1995. Blood-brain barrier disruption on contrast-enhanced MRI in patients with 
mild relapsing-remitting multiple sclerosis: Relationship to course, gender, and 
age. Neurology, 45, 1122-1126. 
Supajatura, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C., & Ogawa, H. 2002. 
Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate 
immunity. J Clin Invest, 109, 1351-1359. 
Taildeman, J., Perez-Novo, C. A., Rottiers, I., Ferdinande, L., Waeytens, A., De, Colvenaer, 
V, Bachert, C., Demetter, P., Waelput, W., Braet, K., & Cuvelier, C. A. 2009. Human 
mast cells express leptin and leptin receptors. Histochem.Cell Biol., 131, 6, pp. 703-
711. 
Teunis, M. A., Heijnen, C. J., Sluyter, F., Bakker, J. M., Van Dam, A. M., Hof, M., Cools, A. R., 
& Kavelaars, A. 2002. Maternal deprivation of rat pups increases clinical symptoms 
of experimental autoimmune encephalomyelitis at adult age. J.Neuroimmunol., 133, 
1-2, pp. 30-38. 
Thaxton, J. E., Nevers, T. A., & Sharma, S. 2010. TLR-mediated preterm birth in response to 
pathogenic agents. Infect.Dis.Obstet.Gynecol., 2010,  
Theoharides, T. C. 2009. Autism spectrum disorders and mastocytosis. Int J Immunopathol 
Pharmacol, 22, 4, pp. 859-865. 
Theoharides, T. C., Angelidou, A., Alysandratos, K. D., Zhang, B., Asadi, S., Francis, K., 
Toniato, E., & Kalogeromitros, D. 2011. Mast cell activation and autism. 
Biochim.Biophys.Acta, (Dec 23) [Ahead of print]. 
Theoharides, T. C.,Cochrane, D. E. 2004. Critical role of mast cells in inflammatory diseases 
and the effect of acute stress. J Neuroimmunol, 146, 1-12. 
Theoharides, T. C., Donelan, J. M., Papadopoulou, N., Cao, J., Kempuraj, D., & Conti, P. 
2004. Mast cells as targets of corticotropin-releasing factor and related peptides. 
Trends Pharmacol Sci, 25, 563-568. 
www.intechopen.com
 
Perinatal Immune Activation and Risk of Autism 
 
287 
Theoharides, T. C.,Doyle, R. 2008. Autism, gut-blood-brain barrier and mast cells. J Clin 
Psychopharmacol, 28, 5, pp. 479-483. 
Theoharides, T. C., Doyle, R., Francis, K., Conti, P., & Kalogeromitros, D. 2008. Novel 
therapeutic targets for autism. Trends Pharmacol Sci., 29, 8, pp. 375-382. 
Theoharides, T. C.,Kalogeromitros, D. 2006. The critical role of mast cell in allergy and 
inflammation. Ann NY Acad Sci, 1088, 78-99. 
Theoharides, T. C., Kempuraj, D., & Iliopoulou, B. P. 2007a. Mast cells, T cells, and inhibition 
by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. 
Advances in Experimental Medicine and Biology, 601, 423-430. 
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. 2007b. 
Differential release of mast cell mediators and the pathogenesis of inflammation. 
Immunol Rev, 217, 65-78. 
Theoharides, T. C.,Konstantinidou, A. 2007. Corticotropin-releasing hormone and the blood-
brain-barrier. Front Biosci, 12, 1615-1628. 
Theoharides, T. C., Zhang, B., Kempuraj, D., Tagen, M., Vasiadi, M., Angelidou, A., 
Alysandratos, K. D., Kalogeromitros, D., Asadi, S., Stavrianeas, N., Peterson, E., 
Leeman, S., & Conti, P. 2010. IL-33 augments substance P-induced VEGFsecretion 
from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A, 
107, 9, pp. 4448-4453. 
Torigoe, C., Goldstein, B., Wofsy, C., & Metzger, H. 1997. Shuttling of initiating kinase 
between discrete aggregates of the high affinity receptor for IgE regulates the 
cellular response. Proc.Natl.Acad.Sci.U.S.A, 94, 4, pp. 1372-1377. 
Torrente, F., Ashwood, P., Day, R., Machado, N., Furlano, R. I., Anthony, A., Davies, S. E., 
Wakefield, A. J., Thomson, M. A., Walker-Smith, J. A., & Murch, S. H. 2002. Small 
intestinal enteropathy with epithelial IgG and complement deposition in children 
with regressive autism. Mol.Psychiatry, 7, 4, pp. 375-82, 334. 
Torricelli, M., Novembri, R., Bloise, E., De, Bonis M., Challis, J. R., & Petraglia, F. 2011. 
Changes in placental CRH, urocortins, and CRH-receptor mRNA expression 
associated with preterm delivery and chorioamnionitis. J Clin Endocrinol.Metab, 96, 
2, pp. 534-540. 
Varadaradjalou, S., Feger, F., Thieblemont, N., Hamouda, N. B., Pleau, J. M., Dy, M., & 
Arock, M. 2003. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human 
mast cells. Eur J Immunol, 33, 899-906. 
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. 2005. 
Neuroglial activation and neuroinflammation in the brain of patients with autism. 
Ann.Neurol., 57, 1, pp. 67-81. 
Vickers, M. H., Gluckman, P. D., Coveny, A. H., Hofman, P. L., Cutfield, W. S., Gertler, A., 
Breier, B. H., & Harris, M. 2005. Neonatal leptin treatment reverses developmental 
programming. Endocrinology, 146, 10, pp. 4211-4216. 
Viora, M., Quaranta, M. G., Straface, E., Vari, R., Masella, R., & Malorni, W. 2001. Redox 
imbalance and immune functions: opposite effects of oxidized low-density 
lipoproteins and N-acetylcysteine. Immunology, 104, 4, pp. 431-438. 
Vojdani, A., Campbell, A. W., Anyanwu, E., Kashanian, A., Bock, K., & Vojdani, E. 2002. 
Antibodies to neuron-specific antigens in children with autism: possible cross-
reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and 
Streptococcus group A. J Neuroimmunol., 129, 1-2, pp. 168-177. 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
288 
Volpe, J. J. 2009. The encephalopathy of prematurity--brain injury and impaired brain 
development inextricably intertwined. Semin.Pediatr Neurol, 16, 4, pp. 167-178. 
Warren, W. B., Patrick, S. L., & Goland, R. S. 1992. Elevated maternal plasma corticotropin-
releasing hormone levels in pregnancies complicated by preterm labor. Am J Obstet 
Gynecol, 166, 1198-204. 
Weaver, I. C., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., 
Dymov, S., Szyf, M., & Meaney, M. J. 2004. Epigenetic programming by maternal 
behavior. Nat.Neurosci., 7, 8, pp. 847-854. 
Weiss, L. A., Arking, D. E., Daly, M. J., & Chakravarti, A. 2009. A genome-wide linkage and 
association scan reveals novel loci for autism. Nature, 461, 7265, pp. 802-808. 
Wilkerson, D. S., Volpe, A. G., Dean, R. S., & Titus, J. B. 2002. Perinatal complications as 
predictors of infantile autism. Int J Neurosci., 112, 9, pp. 1085-1098. 
Wills, S., Cabanlit, M., Bennett, J., Ashwood, P., Amaral, D., & Van de Water, J. 2007. 
Autoantibodies in autism spectrum disorders (ASD). Ann.N.Y.Acad.Sci., 1107, 79-91. 
Wills, S., Cabanlit, M., Bennett, J., Ashwood, P., Amaral, D. G., & Van de Water, J. 2008. 
Detection of autoantibodies to neural cells of the cerebellum in the plasma of 
subjects with autism spectrum disorders. Brain Behav.Immun., 23, 64-74. 
Yasuoka, S., Kawanokuchi, J., Parajuli, B., Jin, S., Doi, Y., Noda, M., Sonobe, Y., Takeuchi, H., 
Mizuno, T., & Suzumura, A. 2011. Production and functions of IL-33 in the central 
nervous system. Brain Res, add 1385:8-17. 
Young, H. A., Geier, D. A., & Geier, M. R. 2008. Thimerosal exposure in infants and 
neurodevelopmental disorders: an assessment of computerized medical records in 
the Vaccine Safety Datalink. J Neurol Sci, 271, 1-2, pp. 110-118. 
Zappella, M. 2010. Autistic regression with and without EEG abnormalities followed by 
favourable outcome. Brain Dev., 32, 9, pp. 739-745. 
Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S, Theoharides A., 
Sideri, k., Lykouras L, Kalogeromitros D, & Theoharides TC. 2010. Mitochondrial 
DNA and anti-mitochondrial antibodies in serum of autistic children. J 
Neuroinflammation, 7, 1, pp. 80. 
Zhang, T. Y.,Meaney, M. J. 2010. Epigenetics and the environmental regulation of the 
genome and its function. Annu.Rev Psychol., 61, 439-3. 
Zimmerman, A. W., Connors, S. L., Matteson, K. J., Lee, L. C., Singer, H. S., Castaneda, J. A., 
& Pearce, D. A. 2007. Maternal antibrain antibodies in autism. Brain Behav.Immun., 
21, 3, pp. 351-357. 
www.intechopen.com
Autism - A Neurodevelopmental Journey from Genes to Behaviour
Edited by Dr. Valsamma Eapen
ISBN 978-953-307-493-1
Hard cover, 484 pages
Publisher InTech
Published online 17, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book covers some of the key research developments in autism and brings together the current state of
evidence on the neurobiologic understanding of this intriguing disorder. The pathogenetic mechanisms are
explored by contributors from diverse perspectives including genetics, neuroimaging, neuroanatomy,
neurophysiology, neurochemistry, neuroimmunology, neuroendocrinology, functional organization of the brain
and clinical applications from the role of diet to vaccines. It is hoped that understanding these interconnected
neurobiological systems, the programming of which is genetically modulated during neurodevelopment and
mediated through a range of neuropeptides and interacting neurotransmitter systems, would no doubt assist in
developing interventions that accommodate the way the brains of individuals with autism function. In keeping
with the multimodal and diverse origins of the disorder, a wide range of topics is covered and these include
genetic underpinnings and environmental modulation leading to epigenetic changes in the aetiology; neural
substrates, potential biomarkers and endophenotypes that underlie clinical characteristics; as well as
neurochemical pathways and pathophysiological mechanisms that pave the way for therapeutic interventions.
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